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Abstract Protein kinase C (PKC) activity in the muscular layer
of stem villi vessels from the human term placenta was studied.
Resting state PKC activity was distributed evenly between the
cytosol and the particulate fractions. Upon stimulation by three
different activators, phorbol 12-myristate 13-acetate, fluoride
and endothelin-1, a translocation of PKC activity from the
cytosolic to the particulate fraction was observed. The expression
and distribution of PKC isoforms were then examined by
Western blot analysis using specific antibodies to PKC isoforms.
At least four PKC isoforms, PKCK, PKCL1, PKCL2, PKCj, and
trace amounts of PKCO were detected in both fractions. Their
relative responses to the different agonists were examined by
quantifying their subcellular redistribution. No significant
differential activation of the four mainly expressed PKC
isoforms were observed in response to stimulation with any of
the stimuli. Moreover, our results show that endothelin-1 induced
translocation/activation of PKC in this vascular smooth muscle.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Protein kinase C (PKC) plays a fundamental role in the
regulation of many signal transduction mechanisms activated
in response to a variety of stimuli (hormones, growth factors,
neurotransmitters). Molecular cloning and biochemical studies
have revealed that this kinase consists of a family of at least
12 closely related isoforms classi¢ed into four groups based on
their primary structure and cofactor requirements. The con-
ventional cPKCs (K, L1, L2 and Q) are Ca2-dependent and are
activated by diacylglycerol (DAG) and phorbol esters. The
novel nPKCs (N, O, R and a) are Ca2-independent and require
DAG or phorbol ester for activation. The atypical aPKCs (j,
V, S) are Ca2-independent and are not activated by DAG or
by phorbol esters. A Ca2-independent isoform, PKCW, has
recently been identi¢ed. The patterns of their intracellular and
tissue distributions suggest that each PKC isoform regulates
speci¢c cellular pathways leading to speci¢c responses [1].
PKC isoforms are present in all tissues to varying degrees.
Some isoforms are ubiquitous (PKCK, PKCj), while others
are present in only a few tissues.
PKC appears to perform a variety of functions in vascular
smooth muscle. Many studies have reported that the activa-
tion of PKC is associated with vascular smooth muscle con-
tractility and plays a major role in growth-related signal trans-
duction [2].
The feto-placental circulation provides for the metabolic
needs of the fetus, and regulation of blood £ow in this system
is critical for fetal well-being and normal development. Stem
villi vessels are considered to be the major sites of fetal pla-
centa vascular resistance [3]. Since the placental vessels lack
autonomic innervation, vascular tone is regulated by locally
or humorally delivered vasoactive substances [4]. Endothelin-1
(ET-1), a 21 amino acid peptide, is a potent vasoactive agent
that acts on the contractility of placental vessels [5]. Several
studies have reported that activation of PKC may be a com-
ponent of the signal cascade resulting in the e¡ects of this
peptide on contractility and cell division in vascular smooth
muscles, such as rat cardiomyocytes [6^8], bovine cerebral
arteries [9], human and rat renal artery [10,11], rat aorta
[12] and the rat portal vein [13]. Speci¢c high a⁄nity binding
sites for ET-1 have been described in the muscular layer of
stem villi vessels [14], and Mondon et al. [15] demonstrated
that these ET-1 vascular binding sites are coupled to a phos-
phoinositide-speci¢c phospholipase C pathway that generates
two intracellular messengers, DAG and Ca2, that are activa-
tors of PKC.
The objective of this study was to examine the presence of
PKC activity in the muscular layer of human placental stem
villi vessels. The expression and distribution of PKC isoforms
were then determined by Western blot analysis using speci¢c
antibodies to PKC isoforms. Activation of PKC by three dif-
ferent stimuli, ET-1, a phosphoinositide-coupled agonist, £u-
oride, a G-protein activator, and phorbol 12-myristate 13-ace-
tate, a direct activator, was assessed by measuring its
translocation from the cytosolic to the particulate fractions.
For this purpose, two approaches were used: the redistribu-
tion of PKC enzyme activity measured by phosphorylation of
an exogenous substrate, and an increase in particulate-associ-
ated PKC immunoreactivity determined by Western blot anal-
ysis.
2. Materials and methods
2.1. Chemicals
[Q32-P]ATP (3000 Ci/mmol), Hybond-C membranes, the enhanced
chemiluminescence detection system (ECL) and X-ray ¢lms were ob-
tained from Amersham International (Buckinghamshire, UK). Phor-
bol 12-myristate 13-acetate (PMA), 4K-phorbol 12,13-didecanoate
(4KPDD), leupeptin, Nonidet P-40, histone H1 (type III S), phospha-
tidylserine, 1,3-diolein, phenylmethylsulfonyl £uoride (PMSF) and
other drugs and chemicals were of the highest quality available
from Sigma (St, Louis, MO, USA).
Antibodies against PKCK, PKCN, PKCO and PKCj were from
Gibco BRL (Cergy Pontoise, France). They were raised in rabbits
against peptides 313^326 from PKCK, 662^673 from PKCN, 726^
737 from PKCO and 577^592 from PKCj. Antibodies against PKCL1
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and PKCL2 were from Santa Cruz Biotechnology Inc. (Le Perray en
Yvelines, France). They were raised in rabbits against peptides corre-
sponding to amino acid sequences 656^671 and 657^673. The secon-
dary antibody, donkey anti-rabbit IgG conjugated to horseradish per-
oxidase, was purchased from Amersham. Endothelin-1 (ET-1) was
supplied by Neosystem Laboratoire (Strasbourg, France). DEAE-cel-
lulose (DE-52) was obtained from Whatman and prestained molecular
weight markers were from Bio-Rad.
2.2. Placenta
Human placentas were obtained from normal term pregnancies
immediately after vaginal delivery. Placental tissue was excised be-
tween the basal and chorionic plates and stem villi vessels were dis-
sected as reported previously [15].
2.3. Stimulation and preparation of subcellular fractions
Samples of stem villi vessel smooth muscle (150^200 mg) were
placed in 1.5^2 ml Krebs Ringer bu¡er (KRB) containing 12 mM
glucose and incubated at 37‡C for 15 min under an atmosphere of
95% O2-5% CO2. The e¡ectors were then added for various times and
the reactions were stopped by cooling to 4‡C. Enzyme was extracted
by homogenizing the tissue in 5 volumes of 20 mM Tris-HCl bu¡er,
pH 7.5, containing 250 mM sucrose, 1 mM EGTA, 2 mM EDTA, 50
mM mercaptoethanol, 2 mM PMSF plus 5% glycerol and 20 Wg/ml
leupeptin using an Ultra-Turrax apparatus. The homogenate was cen-
trifuged at 1000Ug for 15 min to remove debris and nuclei ; the super-
natant was then ultracentrifuged for 60 min at 100 000Ug. The result-
ing supernatant (cytosol) was removed and stored at 4‡C. The pellet
was resuspended in the homogenization medium containing 1% Non-
idet P-40, gently mixed for 45 min on ice and centrifuged at
100 000Ug for 30 min. The resulting supernatant was the solubilized
particulate PKC fraction.
Protein kinase C was partially puri¢ed from the cytosolic and par-
ticulate fractions by DEAE-cellulose chromatography. Samples were
loaded onto DE-52 columns (5 ml bed volume) equilibrated with 20
mM Tris-HCl bu¡er, pH 7.5, containing 1 mM EDTA, 1 mM EGTA,
10 mM mercaptoethanol, 5% glycerol and 20 Wg/ml leupeptin. The
columns were washed with 3 volumes of the same bu¡er and PKC
was eluted stepwise with bu¡er containing 120 and 200 mM NaCl.
Fractions of 1 ml were collected and assayed for PKC activity.
2.4. Protein kinase C activity assay
Protein kinase C activity was determined by measuring the transfer
of 32P from [Q-32P]ATP to histone III S. Aliquots of each sample
(50 Wl) were incubated in a reaction mixture (¢nal volume 250 Wl)
containing 20 mM Tris-HCl, pH 7.5, 4 mM MgCl2, 100 WM ATP,
2 WCi/ml [Q-32P]ATP, 0.6 mM Ca2, 160 Wg/ml histone III S, 20 Wg/ml
phosphatidylserine and 3 Wg/ml 1,2-diolein. The reaction was initiated
by adding [Q-32P]ATP. Each fraction was incubated without phospho-
lipids and Ca2 but with 1 mM EGTA for 5 min at 30‡C. Incubation
was stopped by adding 1 ml 20% ice-cold (w/v) trichloroacetic acid
(TCA) in 10 mM potassium monophosphate followed by 500 Wg of
BSA added as carrier. The mixture was centrifuged (2500Ug, 15 min)
and the resulting pellet was solubilized with 1 N NaOH and precipi-
tated again with TCA. This procedure was repeated twice. Finally, the
pellet was dissolved in 1 N NaOH and its radioactivity was counted
by liquid scintillation. PKC activity is expressed as the di¡erence
between the activity assayed with and without Ca2, phosphatidylser-
ine and diolein. Values are counts per min/mg protein. Protein was
assayed by the Bradford method [16].
2.5. Western blot analysis
Samples of cytosolic and particulate fraction protein were separated
by SDS-PAGE on 8% gels according to the method of Laemmli [17].
The separated proteins were electrophoretically transferred to a nitro-
cellulose membrane overnight. Non-speci¢c binding sites were blocked
by incubating the membrane with 5% fat-free dried milk in TBST (10
mM Tris-HCl, pH 7.5, 0.15 M NaCl, 0.05% Tween 20). Anti-PKC
antibodies were added at the appropriate concentration and incubated
for di¡erent times at room temperature. The membrane was washed
with TBST and incubated with the secondary antibody. The blots
were developed using ECL reagents, visualized on Kodak X-ray ¢lms
and the immunoreactive bands were quanti¢ed by densitometric scan-
ning (Studio Scann IISI, Agfa). Rat brain protein extracts were run in
parallel as positive controls for the detection of PKC isoforms.
2.6. Data analysis
Student’s unpaired t-test was used to determine statistical signi¢-
cance. P values of less than 0.05 were considered to be signi¢cant.
3. Results
3.1. Characterization and activation of protein kinase C
PKC activity was present in both the cytosolic and partic-
ulate fractions prepared from unstimulated stem villi vessels
of human term placenta. DEAE-cellulose column chromatog-
raphy (Fig. 1) showed a main peak of phospholipid- and
Ca2-dependent activity eluted with bu¡er containing 120
mM NaCl. The second peak, eluted with 200 mM NaCl,
was not regulated by Ca2 or by phospholipid, and may
have been the proteolytically generated catalytic domain of
the enzyme (PKM). Unstimulated PKC activity was nearly
equally distributed between the soluble (56 þ 8%) and partic-
ulate fractions (44 þ 7%) (n = 6).
Incubation with increasing concentrations of PMA, a po-
tent phorbol ester, for 15 min, caused a gradual loss of PKC
activity from the cytosol. The maximal e¡ect (89 þ 4% loss)
occurred with 1 WM PMA (Fig. 2A). This decrease was corre-
lated with a parallel increase in particulate-bound PKC activ-
ity (up to 6-fold) (Fig. 2B). In contrast, the biologically in-
active phorbol ester, 4KPDD, was without signi¢cant e¡ect.
Incubation of stem villi vessel samples with ET-1 resulted in a
moderate but signi¢cant change in PKC activity from the
cytosol towards the particulate fraction. ET-1 (1 WM) de-
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Fig. 1. Chromatography of cytosolic and particulate-associated pro-
tein kinase C from human placental stem villi vessels on a DEAE-
cellulose column. PKC activity in the eluted fractions was assayed
as described in Section 2 and is expressed cpm: (b) in the presence
of Ca2, phosphatidylserine and diolein, (a) in the presence of
EGTA, without phosphatidylserine or diolein. Results are represen-
tative of three experiments.
Fig. 2. E¡ects of PMA and 4KPDD on PKC activity in the cyto-
solic (A) and particulate fractions (B) of human placental stem villi
vessels. PKC activity was determined as described in Section 2.
Data are means þ S.E.M. for three series of experiments done in
triplicate. *P6 0.05, **P6 0.01 compared with the control value.
C. Tertrin-Clary et al./FEBS Letters 422 (1998) 123^128124
creased cytosolic PKC activity (43 þ 10%) and increased the
particulate fraction activity (up to 3-fold). Incubation with 25
mM NaF, a direct activator of G-proteins, also changed the
subcellular distribution of PKC activity: a 63 þ 10% decrease
in the cytosolic fraction and a 2-fold increase in the particu-
late fraction (Fig. 3A,B).
3.2. Identi¢cation and intracellular distribution of PKC
isoforms
Isozyme-speci¢c antibodies were used to show the presence
of at least ¢ve PKC isoforms in the cytosol and particulate
fractions of the muscular layer of stem villi vessels in human
term placenta. The main ones were PKCK, PKCL1, PKCL2,
and PKCj, with traces of PKCO (Fig. 4). Molecular weight
markers were run in parallel and all the isoforms examined
were compared to rat brain cytosolic extracts. The speci¢city
of each immunoreactive band was shown by running the blots
with the appropriate peptide antigens.
PKCK gave a single immunoreactive band at approximately
80 kDa. It was mainly in the particulate fraction, although
there was a weak signal in the cytosolic extract. Several bands
were recognized by PKCL1 antibody: two major bands with
apparent molecular weights of 80 and 76 kDa and smaller
minor immunoreactive bands. All these forms were present
in both fractions and were not detected by PKCL1 antibody
incubated with the corresponding antigenic peptide. Thus, the
major bands may represent intact PKCL1 and the minor ones
may be modi¢ed forms generated by proteolysis. Several
forms of PKCL2 were also detected. There was a band at
approximately 80 kDa, mainly in the particulate fraction,
and additional bands of lower apparent molecular weights,
all blocked by the peptide antigen. The isoforms PKCQ and
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Fig. 4. Representative immunoblot analysis of PKC isoforms in the cytosol and particulate fractions isolated from human placental stem villi
vessels. Samples of cytosolic (C) and particulate (P) fractions were prepared and analyzed as described in Section 2. Proteins (80 Wg/lane) were
separated on 8% SDS-PAGE, transferred to a nitrocellulose membrane and immunoblotted with isoform-speci¢c anti-PKC antisera. The specif-
icity of staining was con¢rmed by preincubating antisera with (+) and without (3) the appropriate peptide antigen. B: A rat brain cytosol frac-
tion used as positive control. Arrows indicate the positions of the molecular weight markers (kDa).
Table 1
Percent distribution of PKC isoforms in the cytosolic and particu-
late fractions of human placental stem villi vessels
Isoform Distribution (%)
Cytosolic Particulate
K 15 þ 2 85 þ 3
L1 40 þ 4 60 þ 4
L2 25 þ 3 75 þ 5
O 35 þ 7 65 þ 6
j 40 þ 5 60 þ 8
Cytosol and particulate samples were analyzed by SDS-PAGE and
immunoblotted using PKC-isoform speci¢c antisera, as described in
Section 2. Speci¢c immunoreactive bands were quanti¢ed by densito-
metric scanning. The values are percent of total band intensity.
Values are means þ S.E.M. of three experiments.
Fig. 3. E¡ects of NaF and ET-1 on PKC activity in the cytosolic
(A) and particulate fractions (B) of human placental stem villi ves-
sels. PKC activity was determined as described in Section 2. Data
are means þ S.E.M. of three series of experiments done in triplicate.
*P6 0.05, **P6 0.01 compared with the control value.
C. Tertrin-Clary et al./FEBS Letters 422 (1998) 123^128 125
PKCN were not detected in conditions which revealed their
presence in a rat brain control, even when large amounts of
protein (up to 120 Wg) were run. PKCO was poorly repre-
sented, and was detected as a single speci¢c band with an
apparent molecular weight of 90 kDa in both fractions,
mostly in the particulate fraction. In contrast, PKCj appeared
as a doublet with estimated molecular weights of 80^76 kDa.
The other isoforms were not investigated.
The amounts of these isoforms were not quanti¢ed, since
the antisera had di¡erent a⁄nities for their respective antigen
and thus for the corresponding PKC isoforms. However, den-
sitometric analysis of the relative amounts of the cytosol and
particulate forms for a given isoform were determined. Table
1 shows that all the isoforms were found mainly in the partic-
ulate fraction.
3.3. Subcellular redistribution of PKC isoforms
The subcellular redistribution of the four chie£y expressed
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Fig. 5. Changes in distribution of immunoreactive PKCK, PKCL1, PKCL2, and PKCj of human placental stem villi vessels stimulated for 2
and 15 min in the presence of either 1 WM ET-1, 1 WM PMA or 25 mM NaF. Proteins from the cytosolic (40 Wg) and particulate (30 Wg) frac-
tions were analyzed as described in Fig. 4. The results shown are representative of two experiments. The upper panels show immunoblots of cy-
tosolic and particulate fractions. The lower panels show the quanti¢cation by scanning densitometry of the immunoblots from cytosolic (a)
and particulate fractions (b).
C. Tertrin-Clary et al./FEBS Letters 422 (1998) 123^128126
PKC isoforms in response to treatment with ET-1, PMA and
NaF was examined by Western blot analysis (Fig. 5). All the
PKC isoforms were translocated from the cytosolic to the
particulate fractions upon stimulation. Treatment with either
1 WM ET-1, 1 WM PMA or 25 mM NaF for 15 min resulted in
a time-dependent loss of PKCL1, PKCL2 and PKCj in the
cytosolic fractions, with a concomitant increase in particu-
late-associated immunoreactive PKCL1, and PKCL2. The de-
crease in PKCK in the soluble fraction was not analyzed be-
cause this isoform is weakly expressed in this fraction (15% of
total PKCK). Although a decrease in cytosolic PKCj was
observed upon stimulation by these di¡erent stimuli (50%
loss), no signi¢cant increases in particulate-associated immu-
noreactive PKCj were detected. These stimuli were more ef-
fective in increasing particulate-associated PKCL2 (up to 4-
fold above the control values) than PKCK and PKCL1 (2-
fold and 3-fold above the control values).
4. Discussion
This study demonstrates the presence of protein kinase C in
the muscular layer of stem villi vessels from human term
placenta. Both cytosol and particulate PKC activities were
eluted as single peaks from DEAE-cellulose. Under basal (un-
stimulated) conditions, PKC activity appears to be equally
distributed between the soluble (cytosol) and particulate-asso-
ciated forms. A similar high percentage of particulate-bound
PKC activity has been reported in some metabolically active
tissues such as brain, liver, and skeletal muscles, and may be a
preactivated form of PKC.
It is generally agreed that activation of PKC is associated
with its redistribution to several intracellular compartments
where endogenous protein substrates are presumably located
[1]. Therefore, the translocation of PKC activity from the
cytosol to the particulate fraction is an index of enzyme stim-
ulation [18]. PMA, a potent activator of this kinase, causes
almost complete loss of PKC activity from the cytosolic frac-
tion, and a marked increase in the particulate fraction. In
contrast, the inactive phorbol ester 4KPDD was without ef-
fect, indicating that the translocation of PKC induced by
PMA is associated with the activation of PKC. ET-1 pro-
duced a moderate but signi¢cant redistribution of PKC activ-
ity. It is well known that physiological agonists produce more
transient and less intense signals than those induced by direct
activators such as PMA. The positive e¡ect of £uoride is
evidence that PKC activation is mediated by the stimulation
of G-protein(s). This complements and extends previous data
showing that ET-1 [15] and £uoride (Mondon, personal com-
munication) cause the accumulation of inositol phosphates in
stem villi vessels, suggesting that ET-1 activates PKC via a G-
protein(s)-coupled phosphoinositide breakdown.
Using Western blot we detected the presence of at least ¢ve
PKC isoforms (PKCK, PKCL1, PKCL2, PKCO and PKCj) in
this vascular smooth muscle. PKCQ and PKCN were not de-
tected and other isoforms were not assayed. The apparent
molecular weights of these proteins, determined by compari-
son with molecular weight markers, are close to the published
values. The presence of each isoform was con¢rmed by com-
parison with the immunoreactive bands observed in rat brain
cytosol extracts. The immunospeci¢city of the bands was also
checked by performing the blots in the presence of the appro-
priate peptide antigen. The relative amount of each PKC iso-
form is di⁄cult to determine, since the antibodies had di¡er-
ent binding a⁄nities. All the isoforms were present in both the
cytosol and particulate fractions. Quantitation of immunore-
active bands revealed that all the PKC isoforms are mainly in
the particulate fraction, and therefore presumably active. This
result is in agreement with enzyme activity data showing a
high content of particulate-bound PKC activity. Ruzycky et
al. [19] recently reported that the majority of human placental
syncytiotrophoblast PKC was bound to the plasma mem-
branes.
PKCK, an ubiquitous isoform, appears to play a general
role in cell physiology and seems to be involved in the regu-
lation of rat coronary smooth muscle cell proliferation [20].
The two splice variants of PKCL, PKCL1 and PKCL2, de-
tected in stem villi vessels, have been identi¢ed in a variety
of tissues in a variable ratio. PKCL2 became associated with
actin ¢laments when activated [21], suggesting its involvement
in the contractile process. It should be noted that feto-placen-
tal vessels contain a large amount of K-smooth muscle actin
isoform [22]. The absence of PKCQ was expected, since this
isoform is mainly found in the brain or brain-derived tissues.
Nevertheless, it has been found in some cell lines [23] and in
the human syncytiotrophoblast [19]. We found no evidence
for PKCN, although this isoform appears to be abundant in
several vascular smooth muscles [24], and PKCO was poorly
detected. This latter isoform seems to be involved in Ca2-
independent contraction in the ferret aorta [25]. In contrast,
the immunoreactivity of the atypical isoform PKCj was in-
tense, suggesting that this isoform is present in high amounts.
This isoform was detected as a speci¢c doublet of immunore-
active bands, as in several other tissues and cell types. They
may represent di¡erent phosphorylated states of the isoform,
though it is possible that one band may be due to cross-re-
action with conventional PKC isoforms [26]. This widely dis-
tributed isoform appears to play a signi¢cant role in the mi-
togenic pathway [27] by linking membrane signalling to
nuclear events.
The existence of PKC isoforms from three distinct groups
and the presence of both Ca2-dependent and Ca2-independ-
ent isoforms indicate that PKC plays a complex, multifunc-
tional regulatory role in the muscular layer of human placen-
tal stem villi vessels. The presence of Ca2-independent
isoforms of PKC, as in other vascular smooth muscle,
strongly suggests that these isoforms mediate a phosphatidyl
choline hydrolysis-coupled mechanism which generates DAG
without any concomitant mobilization of intracellular Ca2.
This phospholipid degradation has been shown to be involved
in proliferation and di¡erentiation processes.
This pattern of PKC isoforms is consistent with that pre-
viously reported for other vascular smooth muscle cells [2].
PKCK and PKCL are the primary PKC isoforms in rabbit
and rat aorta and in swine carotid artery [28,29] ; PKCO and
PKCj have been found in rat and ferret aorta smooth muscle
cells [25], whereas PKCN was not detected [30]. PKCK, PKCN,
and PKCj have also been identi¢ed in the human renal artery
[25].
The intracellular redistribution of individual PKC isoforms
in response to di¡erent stimuli was then examined. All four
mainly expressed PKC isoforms were translocated from the
cytosolic to the particulate fractions upon stimulation with
either ET-1, PMA or NaF. Apparently there was no di¡er-
ential activation of the various PKC isoforms examined. None
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of the agonists tested led to increases in particulate-associated
PKCj immunoreactivity. A possible translocation of this iso-
form to the nucleus and perinuclear space, as observed in a
variety of cell types including aortic smooth muscles [30],
cannot be excluded. Complex patterns of PKC translocation
have been reported in various tissues and may explain the
diversity of functions modulated by this kinase [31].
The present results show that the increase in particulate-
associated PKC immunoreactivity was associated with en-
hanced Ca2-dependent PKC activity re£ecting PKC activa-
tion. The regulatory role of PKC in vascular smooth muscle
functions ranging from short-term e¡ects (contraction) to
long-term events (cell growth, proliferation, di¡erentiation)
has been demonstrated [1]. This study suggests that in stem
villi vessels, as in other vascular smooth muscles [32^35], PKC
may play a role in mediating ET-1 responses.
In conclusion, our data demonstrate for the ¢rst time the
presence of several PKC isoforms in human placental stem
villi vessels. Stimulation by di¡erent stimuli induced redistrib-
ution of PKC activity from the cytosolic to the particulate
fractions associated with subcellular redistribution of individ-
ual PKC isoforms. The translocation of PKC by ET-1 sug-
gests a potential role of this enzyme in the endothelin-stimu-
lated signalling pathway of the placental stem villi vessels.
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